Moderna (MRNA) Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has reported Accumulated Expenses for 10 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 93.41% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 93.41% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 2.87% from the prior year.
• Accumulated Expenses was $1.9 billion for Q2 2026 at Moderna, roughly flat from $1.9 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.2 billion in Q3 2023 and troughed at $987.0 million in Q2 2025.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 113.55% in 2022 and plunged 38.13% in 2024, its largest moves.
• Over 5 years, Accumulated Expenses stood at $2.1 billion in 2022, then declined by 14.42% to $1.8 billion in 2023, then declined by 20.63% to $1.4 billion in 2024, then slipped by 2.87% to $1.4 billion in 2025, then soared by 37.73% to $1.9 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.9 billion (Q2 2026), $1.9 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.